Search Results
Jun 02, 2026, 14:44 ET Zymo Research Introduces Zymo Services: An Integrated Portfolio Extension Built for High-Impact Scientific Partnership
New genomic services portfolio establishes Zymo as a premier NGS partner, offering end-to-end solutions built on proven technology and deep scientific expertiseIRVINE, Calif., June 2, 2026 /PRNewswire/ -- Zymo
More news about: Zymo Research Corp.
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
10.1097/JTO.0b013e3182779d18. 17 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore. 18
More news about: Johnson & Johnson
May 28, 2026, 12:30 ET Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to accelerate the shift toward genomics in cancer testing and as a standard of care
More news about: Illumina, Inc.
May 26, 2026, 08:30 ET ePlus Launches Private AI Infrastructure Managed Service
NVIDIAHERNDON, VA, May 26, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
May 22, 2026, 09:58 ET dashmoto® und das Atlassian Williams F1 Team präsentieren offiziell den dash 3 Williams Edition Performance Elektroroller
Produktdesign hinausgeht. Für den Gründer von dashmoto®, Kim Ng, ist das Streben nach Leistung etwas sehr Persönliches. Als ehemaliger Rennfahrer war Ngs frühe Karriere geprägt von einer unerbittlichen Verbindung zu Geschwindigkeit, Präzision und dem Gefühl, die volle Kontrolle über die Bewegung zu haben.
More news about: dashmoto
May 22, 2026, 04:00 ET dashmoto® and Atlassian Williams F1 Team officially launch the dash 3 Williams edition performance electric scooter
reaches far beyond product design. For dashmoto® founder Kim Ng, the pursuit of performance is deeply personal. A former competitive driver, Ng's early career was shaped by a relentless connection to speed, precision, and the feeling of being fully in control of motion. That connection became
More news about: dashmoto
May 22, 2026, 04:00 ET dashmoto® and Atlassian Williams F1 Team officially launch the dash 3 Williams edition performance electric scooter
reaches far beyond product design. For dashmoto® founder Kim Ng, the pursuit of performance is deeply personal. A former competitive driver, Ng's early career was shaped by a relentless connection to speed, precision, and the feeling of being fully in control of motion. That connection became
More news about: dashmoto
May 22, 2026, 02:47 ET Gene Solutions 於 TJCC 2026 展示 AI 驅動多體學液態切片創新成果: 推動台灣精準腫瘤醫學發展
驅動運算模型，正逐漸成為提升早期癌症偵測能力的重要關鍵。來自台北榮民總醫院的姜乃榕醫師（Dr. Nai-Jung Chiang）分享液態切片於腸胃道癌症及大腸直腸癌的臨床案例應用經驗，說明整合基因體與轉錄體分析並結合 tumor-informed MRD 的實際臨床價值。姜醫師指出，Gene Solutions 的 K-TRACK 與 K-4CARE 等整合式 NGS 檢測，可提供超越單一位點偵測的生物學精準突變判讀。此外，姜醫師也強調液態切片作為低侵入性檢測工具，在長期監測、復發追蹤及腫瘤異質性評估中的互補價值，特別適用於許多難以反覆取得組織檢體的實體腫瘤。來自臺灣大學醫學院附設醫院的陳偉武醫師（Dr.
More news about: Gene Solutions Genomics Pte., Ltd
May 21, 2026, 18:55 ET ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
HERNDON, Va., May 21, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
May 21, 2026, 03:14 ET Datar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue
de CellDx-Tissue CellDx-Tissue es una prueba de diagnóstico in vitro (DIV) cualitativa que utiliza secuenciación de nueva generación (NGS) dirigida de ADN y ARN aislados de tejido tumoral fijado en formalina e incluido en parafina (FFPE) de pacientes diagnosticados con tumores sólidos.
More news about: Datar Cancer Genetics
May 20, 2026, 06:00 ET Discovery Life Sciences Launches IVDR-Compliant Luminos® Comprehensive with 7-to-10-Day Turnaround for EU Oncology Trials
the addition of a performance study can extend clinical startup by six months or more relative to North America. Most European reference labs offering NGS services either run targeted panels rather than broad CGP, quote 20-to-30-day turnaround, or both, and many Health Institutions lack the project management,
More news about: Discovery Life Sciences
May 19, 2026, 11:06 ET Esoteric Testing Market Outlook 2031: USD 52.34 Billion; Adoption of Precision Diagnostics & Advanced Molecular Testing Driving Growth, Says Mordor Intelligence
systems globally. Technological advancements are playing a crucial role in shaping the market landscape. Innovations in next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, flow cytometry, and advanced immunoassay technologies are improving testing efficiency, sensitivity,
More news about: Mordor Intelligence Private Limited
May 19, 2026, 10:00 ET EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research
technologies worldwide," said Martis Cowles, Ph.D., Chief Business Officer of EpiCypher. "By combining our assay development capabilities with NEB's NGS enzyme and reagent expertise, we can deliver next-generation tools that enable new insights into gene regulation and disease biology."Together,
More news about: New England Biolabs, Inc.
May 18, 2026, 11:45 ET Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research
Test Market Size By Product Type (Test Kits, Reagents & Consumables, Analyzers), By Technology (PCR-Based Testing, Next-Generation Sequencing (NGS), Microarray Analysis, Immunoassays), By Geographic Scope And Forecast
More news about: Verified Market Research
May 18, 2026, 10:01 ET Multiplex Assays Market worth $10.65 billion by 2031 | MarketsandMarkets™
2025.This market is classified into flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), and other techniques. Some of the growth drivers of the flow cytometry segment are its superior sensitivity, multiparametric analysis capability, and
More news about: MarketsandMarkets
May 18, 2026, 08:00 ET Roche Highlights Robust Performance of Ellis Bio SuperMethyl™ Kits in New Tech Spotlight Evaluating Five Low‑Input cfDNA Methyl‑Seq Workflows
research.Drop‑in compatibility with KAPA EvoPrep. Ellis Bio chemistries integrated cleanly with Roche's KAPA EvoPrep library preparation, supporting scalable NGS workflows.Fast workflow option. SuperMethyl Fast provides a shorter bisulfite workflow while still delivering higher conversion efficiency
More news about: Ellis Bio Inc
May 18, 2026, 00:18 ET Datar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren
CellDx-TissueCellDx-Tissue ist ein qualitativer In-vitro-Diagnostiktest (IVD), der gezielte Next-Generation-Sequenzierung (NGS) von DNA und RNA nutzt, die aus formalinfixiertem, in Paraffin eingebettetem (FFPE) Tumorgewebe von Patienten isoliert wurden, bei denen solide Tumoren
More news about: Datar Cancer Genetics
May 15, 2026, 10:00 ET Datar Cancer Genetics 的 CellDx-Tissue 獲得美國 FDA 核准，為該項利用 DNA 與 RNA 進行的實體腫瘤全方位基因體分析檢測寫下里程碑
FDA Breakthrough Device Designations) 互相補足。關於 CellDx-TissueCellDx-Tissue 是一種定性體外診斷 (IVD) 檢測，它利用標靶式次世代定序 (NGS) 技術，對從福爾馬林固定石蠟包埋 (FFPE) 實體腫瘤患者的腫瘤組織中分離的 DNA 及 RNA 進行分析。 此檢測分析 517 個與癌症相關的基因，目的在於提供有關體細胞單核苷酸變異 (SNV)、小片段插入和缺失 (InDels)、ERBB2 基因擴增與涉及 ALK、RET
More news about: Datar Cancer Genetics
May 15, 2026, 09:59 ET Datar Cancer Genetics reçoit l'autorisation de la FDA des États-Unis pour CellDx-Tissue, un test de profilage génomique complet pour les tumeurs solides utilisant l'ADN et l'ARN
CellDx-TissueCellDx-Tissue est un test qualitatif de diagnostic in vitro (DIV) qui utilise le séquençage de nouvelle génération (NGS) ciblé de l'ADN et de l'ARN isolés à partir de tissus tumoraux fixés au formol et inclus en paraffine (FFPE) de patients chez qui on a diagnostiqué des
More news about: Datar Cancer Genetics
May 14, 2026, 11:48 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
platforms.About CellDx-TissueCellDx-Tissue is a qualitative in vitro diagnostic (IVD) test that uses targeted Next-Generation Sequencing (NGS) of DNA and RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue of patients diagnosed with solid tumors. The assay analyses 517 cancer-associated
More news about: Datar Cancer Genetics
May 14, 2026, 11:39 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
platforms.About CellDx-TissueCellDx-Tissue is a qualitative in vitro diagnostic (IVD) test that uses targeted Next-Generation Sequencing (NGS) of DNA and RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue of patients diagnosed with solid tumors. The assay analyses 517 cancer-associated
More news about: Datar Cancer Genetics
May 13, 2026, 10:30 ET Molecular Infectious Disease Testing Market worth $19.09 billion by 2031 | MarketsandMarkets™
includes several methods such as polymerase chain reaction (PCR), isothermal nucleic acid amplification, DNA sequencing, next-generation sequencing (NGS), in situ hybridization, DNA microarrays, and other advanced tests. PCR technology is one of the most commonly used methods due to its high reliability
More news about: MarketsandMarkets
May 11, 2026, 13:33 ET DNA Synthesis Market to Reach $30.4 billion, Globally, by 2035 at 18.2% CAGR: Allied Market Research
and complex genes. The platform supports high-complexity gene constructs of up to 15 kb, with sequences verified through next-generation sequencing (NGS). These products are manufactured and shipped globally from the company's U.S.-based facilities within approximately 10 business days.In November
More news about: Allied Market Research
May 11, 2026, 12:41 ET DNA Polymerase Market to Reach USD 725.8 Million by 2035 as Molecular Diagnostics and High-Fidelity Enzymes Accelerate Precision Genomics
Insights, the market is witnessing rapid transformation driven by the growing adoption of molecular diagnostics, advancements in next-generation sequencing (NGS), expansion of personalized medicine, and increasing demand for high-fidelity DNA amplification technologies across healthcare and biotechnology sectors.
More news about: Future Market Insights
May 11, 2026, 11:40 ET LabGenomics Unifies QDx and IMD Under One Brand
flow cytometry, cytogenetics and chromosomal analysis, Fluorescence In Situ Hybridization (FISH), PCR and RT-PCR assays, next-generation sequencing (NGS) panels, and infectious disease testing. These services provide healthcare providers with access to a broader spectrum of diagnostic insight through
More news about: LabGenomics